2-(2-Methylpropyl)-1,2,3,4-tetrahydroisoquinoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: 2-(2-Methylpropyl)-1,2,3,4-tetrahydroisoquinoline
• 英文别名: 2-isobutyl-1,2,3,4-tetrahydroisoquinoline；2-(2-methylpropyl)-3,4-dihydro-1H-isoquinoline
• 化学式: C₁₃H₁₉N
• 分子量: 189.301
• InChiKey: MCKFHPKZHOUJQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  四氢异喹啉 在 bis(1,5-cyclooctadiene)diiridium(I) dichloride 、 苯硅烷 作用下， 以 甲苯 为溶剂， 反应 18.0h， 生成 2-(2-Methylpropyl)-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  使用羧酸催化胺的还原性N-烷基化

  摘要：

  我们报告了伯胺或仲胺与羧酸的催化还原烷基化反应。两阶段过程涉及硅烷介导的直接酰胺化，然后进行催化还原。

  DOI：

  10.1039/c5cc08881j

文献信息

• PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Castanedo Georgette

  公开号：US20110207713A1

  公开（公告）日：2011-08-25

  Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Formula I 化合物，包括立体异构体、几何异构体、互变异构体、代谢物及其药学上可接受的盐，对抑制 PI3K 的δ异构体以及治疗由脂质激酶介导的疾病，如炎症、免疫性疾病和癌症，具有用途。公开了利用 Formula I 化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病，或相关病理条件的方法。
• Reductive amination of carboxylic acids and [11C]magnesium halide carboxylates
  作者：Cécile Perrio-Huard、Catherine Aubert、Marie-Claire Lasne

  DOI：10.1039/a908991h

  日期：——

  The reductive amination of carboxylic acids was shown to be promoted by 2-chloropyridine hydrochloride (3 eq). It allowed the one-pot preparation of N-alkylamines in yields up to 93% from carboxylic acid (1 eq), amine (1 eq) and sodium borohydride (5 molar eq). The reaction, carried out with [11C]magnesium halide carboxylates (11C, β+, t1/2∶20 min), led to N-[11C]alkylamines in 20–25% radiochemical

  显示出2-氯吡啶盐酸盐（3当量）促进了羧酸的还原胺化。它允许一锅法制备N-烷基胺，其由羧酸（1当量），胺（1当量）和硼氢化钠（5摩尔当量）制备的产率高达93％。用[ 11 C]卤化镁羧酸盐（11 C，β +，t 1/2 ∶20 min）进行的反应以20–25％的放射化学收率产生N- [ 11 C]烷基胺（衰变校正为轰击结束，准备从[ 11 C] CO 2开始的30分钟）。在这种情况下，添加吡啶鎓盐只会导致相应的[ 11C]羧酸。
• NOVEL ISOXAZOLE DRIVATIVE
  申请人：Ishikawa Makoto

  公开号：US20110065739A1

  公开（公告）日：2011-03-17

  Disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an agonistic activity on GPR120 and is therefore useful for the treatment of diabetes, obesity or hyperlipemia. [In formula (I), the A represents a phenyl group which may be substituted by a lower alkoxy group or the like; the 13 represents a bivalent group produced by removing two hydrogen atoms from a benzene ring which may be substituted by a halogen atom or the like; X represents a lower alkylene group having 2 to 4 carbon atoms in its main chain or the like, wherein a carbon atom constituting the main chain may be substituted by an oxygen atom or the like; and Y represents a hydrogen atom or the like.]

  揭示了一种由式(I)表示的化合物或其药学上可接受的盐，该化合物对GPR120具有激动活性，因此对于治疗糖尿病、肥胖或高脂血症是有用的。【在式(I)中，A代表可能被低烷氧基或类似物取代的苯基；13代表通过从苯环中去除两个氢原子而产生的二价基团，该苯环可能被卤素原子或类似物取代；X代表具有2至4个碳原子的低烷基基团或类似物，其中构成主链的碳原子可能被氧原子或类似物取代；Y代表氢原子或类似物。】
• COMPOUNDS USEFUL AS INHIBITORS OF HELIOS PROTEIN
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20210147383A1

  公开（公告）日：2021-05-20

  Disclosed are compounds of Formula (I): or a salt thereof, wherein: Z is CR 6 R 6 or C═O; Ring A is: and R 1 , R 2 , R 3 , R 4 , R 5 , m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.

  公开的化合物为Formula (I)的化合物或其盐，其中：Z为CR6R6或C═O；环A为：而R1、R2、R3、R4、R5、m和n在此处有定义。还公开了使用这些化合物抑制Helios蛋白的方法，以及包含这些化合物的药物组合物。这些化合物在治疗病毒感染和增生性疾病（如癌症）方面非常有用。
• 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE
  申请人：Kubota Hideki

  公开号：US20080227785A1

  公开（公告）日：2008-09-18

  This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.

  本发明涉及一种以BEC 1钾离子通道抑制剂作为活性成分的抗痴呆剂。已经证明，BEC 1钾离子通道抑制剂具有改善学习障碍的作用，并且作为预防或治疗剂是有用的，尤其是对于BEC 1钾离子通道与之相关的疾病，如痴呆症。例如，通过体内试验证实，BEC 1钾离子通道抑制剂具有改善学习障碍的作用。此外，还发现具有2,4,6-三氨基-1,3,5-三嗪的化合物具有BEC 1钾离子通道抑制作用。